The drug, developed by Columbia and MSK researchers, selectively kills cancer cells and has shown activity against multiple malignancies in pre-clinical studies.
Dr. Andrea Califano has won a two-year $200,000 research grant for neuroendocrine cancer research.
According to a recent study, a microsurgical approach is found to be a safe and effective technique to prevent breast cancer-related lymphedema.
Andrea Califano and his investigative team discover a molecular signaling mechanism underlying a specific type of highly aggressive breast cancer.
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
The Columbia Combined Cancer Panel has been granted full approval by the New York State Department of Health.